Furthermore, in accordance to the previous studies associating TPX2 expression with poor survival in lung cancer and astrocytoma, as well as with aggressive disease in meningiomas [53]–[55], our results indicated that TPX2 expression associates with PSA failure, high tumor grade (WHO) and young age in prostate cancer. Here, KLK3 is linked to lung carcinoma.